Login to Your Account

Kenta Biotech Gets CHF12M for Anti-infective Antibodies

By Cormac Sheridan

Wednesday, March 18, 2009
Kenta Biotech AG raised CHF12 million (US$10.1 million) in an internal Series B round that will fund the entry into the clinic of its second therapeutic antibody. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription